RenovoRx (RNXT) Stock: Buy, Sell, or Hold?
RNXT - RenovoRx, Inc. Common Stock
$1.76
-0.01 (-0.56%)
▼
5d:
-25.74%
30d:
+57.14%
90d:
+103.56%
WAIT
LOW Confidence
Analysis Updated: Sep 11, 2026 12:00 AM ET
Earnings: Aug 12, 2026
0d
Get Alerted When RNXT Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: RNXT is down 25.7% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: RNXT is down 25.7% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
In-depth Analysis How we analyze
Valuation Analysis: RNXT is currently trading at $1.76, which is considered slightly high relative to its 30-day fair value range of $1.08 to $1.97.
Technical Outlook: Technically, RNXT is in a uptrend. Immediate support is located at $1.47, while resistance sits at $2.59.
Market Sentiment: RNXT scores 15/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $7.12 (+304.8%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, RNXT is in a uptrend. Immediate support is located at $1.47, while resistance sits at $2.59.
Market Sentiment: RNXT scores 15/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $7.12 (+304.8%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
SLIGHTLY HIGH
Historical Trading Range
$1.08 -
$1.97
Company Quality Score
39/100
(SELL)
Volume Confirmation
HIGH
Confidence Score
42.1%
All Signals
- BEARISH: Weak technical setup (15/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 304.8% below Wall St target ($7.12)
- WARNING: Composite score 39/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$1.08 -
$1.97
Current vs Trading Range
SLIGHTLY HIGH
Support & Resistance Levels
Support Level
$1.47
Resistance Level
$2.59
Current Trend
Uptrend
Technical data as of
Sep 11, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-14.67
Wall Street Target
$7.13
(+304.8%)
Revenue Growth (YoY)
115.4%
Share & Embed Analysis
Last updated: September 13, 2026 7:20 PM ET
Data refreshes hourly during market hours. Next update: 8:20 PM
Data refreshes hourly during market hours. Next update: 8:20 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is RNXT showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
INSM
Insmed Inc |
STRONG BUY
21 analysts |
$200 | 54 HOLD |
|
CRSP
Crispr Therapeutics AG |
BUY
28 analysts |
$88 | 44 HOLD |
|
CYTK
Cytokinetics Inc |
STRONG BUY
21 analysts |
$110 | 53 HOLD |
|
VRTX
Vertex Pharmaceuticals I… |
BUY
34 analysts |
$569 | 38 SELL |
|
CRNX
Crinetics Pharmaceutical… |
STRONG BUY
17 analysts |
$86 | 46 HOLD |
